Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery

IPO Filing:
Septerna, a clinical-stage biotechnology company, has filed for an initial public offering (IPO) to raise up to $100 million, leveraging its strong preclinical data and vision for expanding the druggable GPCR landscape.

GPCR Focus:
The company specializes in G protein-coupled receptor (GPCR) drug discovery, aiming to unlock the full potential of GPCR therapies with its proprietary Native Complex PlatformTM.

Preclinical Data:
Recent preclinical data presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting highlighted the therapeutic potential of Septerna’s oral small molecule parathyroid hormone 1 receptor (PTH1R) agonists for treating hypoparathyroidism.

Lead Product Candidate:
Septerna’s lead product candidate, SEP-786, is a novel, potent, and selective oral small molecule PTH1R agonist currently in Phase 1 clinical development for the treatment of hypoparathyroidism.

Therapeutic Areas: The company focuses on three therapeutic areas:
endocrinology, immunology and inflammation, and metabolic diseases, with a deep pipeline of product candidates.

Platform Technology:
Septerna’s Native Complex PlatformTM recapitulates GPCRs with their natural structure, function, and dynamics, using novel bioengineering outside of the cellular environment, which has led to the discovery and development of its product candidates.